[ad_1] MAPS Public Benefit Corporation (PBC) announced the final participant’s last Evaluation and Exit Planning therapeutic session was completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy for the…
[ad_1] Psychedelics biopharma company Reunion Neuroscience Inc. REUN reported its business update and fiscal results for the second quarter ended September 30, 2022. Reunion’s president and CEO Greg Mayes stated…
[ad_1] Clinical-stage biotech company Mind Medicine (MindMed) Inc. MNMD reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022. For the period,…
[ad_1] The University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances (TCRPS) was created to foster education and research on the field of medical applications of psychedelics, and one…
[ad_1] Tuesday’s midterms will give Americans in some states the chance to vote on members of the House of Representatives, Senate and in 36 states, for Governors. In Colorado, voters will decide whether to legalize psychedelics. If…
[ad_1] Psychedelics mental healthcare firm COMPASS Pathways CMPS reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business…
[ad_1] Psychedelics biotech company Biomind Labs Inc. BMNDF has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT,…
[ad_1] Vancouver-based psychedelics biopharma company Apex Labs Ltd. has received Health Canada’s approval to conduct the first North American take-home clinical trial evaluating the safety and efficacy of multiple low…
[ad_1] Canadian-based producer of mushroom-derived health supplements Psyched Wellness Ltd. PSYCF has successfully completed the production and delivery of customers’ pre-orders of its Amanita muscaria extraction product, Calm, now shipped across…
[ad_1] (Part two of a four-part series) The Palo Santo venture fund invests in private companies. As such, public market movements are not as relevant to them. Nonetheless, these market generations have…
[ad_1] Mental health care company Numinus Wellness NUMIF is re-launching its “Psychedelic Therapy Frontiers” podcast series dedicated to exploring the psychedelics renaissance and cultivating mind, body and spiritual health with…
[ad_1] Ontario Agricultural College’s Department of Plant Agriculture University of Guelph (UG) professors and researchers Dr. Max Jones and Dr. Gale Bozzo received approval by the federal agency Health Canada…
[ad_1] Clinical-stage biopharma company Incannex Healthcare Ltd. IXHL shared its quarterly activities report and appendix 4C for the period ended 30 September 2022, noticeably applying for several U.S. FDA approvals regarding its…
[ad_1] The art world is moving closer to endorsing psychedelics research as witnessed by Nashville-born Daniel Donato’s U.S. concert tour VIP ticket donations. Whether or not you’re familiar with his music, his personal story is truly compelling. As a…
[ad_1] Clinical stage psychedelics company atai Life Sciences ATAI and its majority-owned subsidiary Perception Neuroscience completed patient enrollment for their Phase 2a clinical trial assessing the safety and efficacy of a single…
[ad_1] A five-year license agreement signed between Silo Wellness Inc.’s (OTCQB: SILFF) wholly-owned subsidiary SW Holdings Inc. (SWHI) and Marley Green LLC was terminated by the latter due to the former’s failure to meet its $600,000 in guaranteed minimum royalties…
[ad_1] Canada is hosting discussions on legal access to psychedelic-assisted therapies, especially after Alberta passed regulatory measures for this type of health service. So, does this mean that those who could benefit from these…
[ad_1] The 100 Million Ways Foundation (100MW), a not-for-profit organization focused on harm reduction and improving quality of life of those with opioid use disorders, pulled in nearly $100,000 in…
[ad_1] Researchers at the University of Texas (UT) Dell Medical School in Austin will use brain scans to examine responses following treatment with psilocybin and 5-MeO-DMT for combatants suffering from…
[ad_1] Silo Pharma Inc. SILO has agreed with Columbia University to an extension of the psychedelics biotech company’s option to license certain treatments currently under development, including Alzheimer’s disease and stress-induced anxiety. The…
[ad_1] Small Pharma Inc. DMTTF, a biotech company developing short-acting psychedelic-assisted therapies for diverse mental health disorders, reported its financial results for the three and six months ended August 31,…
[ad_1] Clinical stage biopharma company atai Life Sciences ATAI announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug delivery) technology, with topline results expected…
[ad_1] Psychedelic -or psilocybin- mushrooms have demonstrated a potential to treat such conditions as depression, anxiety and addiction, yet they are still a mystery in terms of how they evolved and what role they play…
[ad_1] Palo Santo Closes $50M Investment Fund Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million…
[ad_1] Consumer health and wellness company LOVE Pharma Co.’s subsidiary The MicroDoz Therapy Inc. is sponsoring a soon-to-commence clinical trial of psilocybin-assisted therapy for cannabis use disorder, to be conducted…